Our mission is to deliver the promise of genetic medicines to complex prevalent diseases. People with AATD have clinical manifestations within the liver and lung organs. AATD is an inherited genetic disorder caused by a single letter change in a gene called SERPINA1.

2 days ago · CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...

2 days ago · KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of ...

Korro Bio is focused on diseases where our platform, OPERA®, can provide a unique solution. We are targeting disease-causing sequences that would be responsive to the safe and targeted editing of RNA. Our current focus areas include the liver and central nervous system.

Discover, develop, and commercialize a new class of RNA therapies informed by human genetics and disease biology to improve the lives of patients with debilitating and life-threatening diseases. Create transformative genetic medicines for diseases with high prevalence.

Find the latest Korro Bio, Inc. (KRRO) stock quote, history, news and other vital information to help you with your stock trading and investing.

Jan 7, 2025 · CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D.,

Feb 28, 2025 · Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua...

2 days ago · Get a real-time Korro Bio, Inc. (KRRO) stock price quote with breaking news, financials, statistics, charts and more.

4 days ago · Korro Bio’s (KRRO) treatment of alpha-1 antitrypsin deficiency received FDA orphan designation, according to a post on the agency’s stie. Published first on TheFly – the ultimate source for ...